News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cellectis (ALCLS)’ UCART19 Receives Advanced-Therapy Medicinal Product Classification From European Medicines Agency


6/23/2014 11:07:03 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Cellectis (Paris:ALCLS) (Alternext: ALCLS.PA), a leader of allogeneic CAR T-cell therapies, is pleased to announce it received a Scientific recommendation from the European Medicines Agency (EMA), in consultation with the European Commission, for UCART19, its lead product candidate in adoptive immunotherapy against CD19 expressing leukemias and lymphomas.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   
Lymphoma
Leukemia

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES